Covid-19 léčba

Hydroxychloroquine (Plaquenil)

  • přehled klinických studií k 14/4/2020 link


  • nepřineslo benefit viz Borba

Borba, 2020. Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study)

Zinc Plus Low Dose Hydroxychloroquine and Azithromycin

Zelenko, 2020. Needs to be reviewed and confirmed by bigger size study.


Caly, 2020. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
Patri, 2020. Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and/or treatment?
Momekov, 2020. Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view
Choudhary, 2020. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance
Schmith, 2020. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19
Bray, 2020. Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors’ responses

Camostat mesylate (Foypan)


  • NCT04352400
  • protease inhibitor – blocking TMPRSS2 
  • info Yakamoto, 2020
  • výzkum probíhá na University of Tokyo a University of Aarhus v Dánsku
  • Wiki

Asakura, 2020. Potential of Heparin and Nafamostat Combination Therapy for COVID-19.
Hoffmann, 2020. Nafamostat mesylate blocks activation of SARS-CoV-2: New treatment option for COVID-19
Bittmann, 2020. TMPRSS2-Inhibitors Play a role in Cell Entry Mechanism of COVID-19: An Insight into Camostat and Nafamostat


Padmanabhan, 2020. Potential dual therapeutic approach against SARS-CoV-2/COVID-19 with Nitazoxanide and Hydroxychloroquine

Kaletra (Lopinavir/Ritonavir)

Abbott Laboratories (ABT)

Arbidol (Umifenovir)

Favipiravir (Avigan)

  • Fujifilm subsidiary Toyama Chemical


Based on favipiravir. RDIF and ChemRar, Russia.


Tocilizumab (Actemra)

Roche Holding AG’s ROG
– IL-6 inhibitor

Siltuximab (Sylvant)

EUSA Pharma
– IL-6 inhibitor

Sarilumab (Kevzara)

Regeneron Pharmaceuticals Inc. REGN + Sanofi SNY
– IL-6R inhibitor

4/7/2020 failed in Phase 3 study link


Gilead (GILD)

  • no effect on mortality, only faster recovery
  • first approved treatment for COVID

Lisinopril (Zestril)
Enalapril (Vasotec)
Benazepril (Lotensin)
Captopril (Capoten)
Fosinopril (Monopril)
Quinapril (Accupril)
human recombinant soluble ACE2 (hrsACE2)


Eli Lilly (LLY)


Tofacitinib (Xeljanz)

Pfizer (PFE)
– JAK inhibitor
– u revmatoidní artritidy
– stejná kategorie léků také ruxolitinib (Jakavi)  Incyte and Novartis, a barticitinib (Olumiant) Eli Lilly

Famotidin (Pepcid)

link generikum.
Merck MRK, +3.14% and Johnson & Johnson JNJ, +0.08%


Liu, 2020. Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction. 
Liu, 2020. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19

Fadraciclib a Seliciclib

  • Cyclacel Pharmaceuticals CYCC
  • CDK inhibitory

20/4/2020 Cyclacel Pharmaceuticals Announces Collaboration With the University of Edinburgh to Study Its CDK Inhibitors to Reduce Runaway Inflammation in COVID-19 Disease

Rintatolimod (Ampligen)

  • Aim ImmunoTech AIM
  • TLR3 agonist

10/4/2020 Japan to test AIM ImmunoTech’s Ampligen for COVID-19
7/4/2020 AIM ImmunoTech and Shenzhen Smoore Technology Announce an Agreement to Research Utilizing an Innovative Smoore Inhalation Delivery Device and Ampligen (rintatolimod) as a Potential, Easy-To-Use Treatment Approach for the SARS-CoV-2 Pandemic


Pluristem Therapeutics (PSTI)
8/5/2020 U.S. FDA Clears Pluristem’s IND Application for Phase II COVID-19 Study


Sorrento Therapeutics (SRNE)
16/5/2020 Covid Report: The Trouble With Tiny Biotech’s Coronavirus Cure Claim


Amarin fish oil EPA drug. Being tested in trials in Canada and Argentina (link).


Statins use linked to lower death rate in COVID patients link




Moderna (MRNA)
Vaccine: mRNA-1273

Capricor (CAPR)
Vaccine: CAP-1002 link 6 pacientů v kritickém stavu, nikdo nezemřel.

Pfizer (PFE)/BioNTech (BNTX)
Vaccine: BNT162
5/9/2020 začínají  fázi 1 v USA

Oxford University
Vaccine: ChAdOx1 nCoV-19

Novavax (NVAX)
Vaccine: NVX-CoV2373
Očekává se zahájení  v květnu.

Sanofi (SNY) / GlaxoSmithKline (GSK)
Klinická studie začne ve 2. pol. 2020